PACAP Inhibitor Program

About Slate Medicines

Slate Medicines is an early-stage biotech targeting the PACAP pathway, a well-validated mechanism in migraine pathophysiology, with next-generation biologics. The company is privately held, pre-revenue, and likely in the preclinical or early clinical development stage, operating in the competitive but high-value neurology therapeutics space. Its success will hinge on demonstrating differentiated efficacy, safety, and convenience compared to existing CGRP-targeting therapies and other PACAP inhibitors in development. With a focused pipeline and a presence in a major biotech hub, Slate aims to carve out a position in the multi-billion dollar migraine market.

Therapeutic Areas

Other Migraine Prevention Drugs